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To determine whether clinical manifestations are asso-
ciated with genotypes or subtypes of Cryptosporidium spp., 
we studied a 4-year longitudinal birth cohort of 533 children 
in Peru. A total of 156 infection episodes were found in 109 
children. Data from ﬁ  rst infections showed that C. hominis 
was associated with diarrhea, nausea, vomiting, general 
malaise, and increased oocyst shedding intensity and dura-
tion. In contrast, C. parvum, C. meleagridis, C. canis, and C. 
felis were associated with diarrhea only. C. hominis subtype 
families were identiﬁ  ed (Ia, Ib, Id, and Ie); all were asso-
ciated with diarrhea. Ib was also associated with nausea, 
vomiting, and general malaise. All C. parvum specimens 
belonged to subtype family IIc. Analysis of risk factors did 
not show associations with speciﬁ  c Cryptosporidium spp. 
genotypes or subtypes. These ﬁ   ndings strongly suggest 
that Cryptosporidium spp. and subtypes are linked to differ-
ent clinical manifestations in children.
C
ryptosporidiosis is often observed as a pediatric dis-
ease in areas where Cryptosporidium spp. are en-
demic. Children <2 years of age are frequently infected in 
theses areas in community (1–4) and hospital (5) settings. 
The spectrum of symptoms is diverse, ranging from acute 
diarrhea, severe chronic diarrhea (6), or vomiting to as-
ymptomatic infections (2,3). In community-based studies 
in Peru, ≈30% of immunocompetent children with cryp-
tosporidiosis reported diarrhea (2,7). In AIDS patients, the 
diversity of symptoms has been linked to immune status; 
severe chronic diarrhea affects patients whose CD4+ counts 
are <200 cells/mm3 (8). A recent study in HIV-infected pa-
tients in Peru showed that only 38% with Cryptosporidium 
infections had diarrhea (9), although 64% of participants 
had CD4+ counts <200 cells/mm3. However, the cause for 
these variations is not clearly understood.
The use of molecular tools in epidemiologic inves-
tigations has provided new insights into the diversity of 
Cryptosporidium spp. infecting humans and animals (10). 
There are at least 16 established Cryptosporidium spp. and 
>40 unnamed genotypes that are potentially different spe-
cies. At least 8 of them have been reported in humans: C. 
hominis, C. parvum, C. meleagridis, C. felis, C. canis, C. 
muris, and C. suis, and the Cryptosporidium cervine geno-
type. Molecular characterization of the 60-kDa glycopro-
tein (GP60) gene of C. hominis and C. parvum has enabled 
further division into subtype families and subtypes (11).
Humans are most frequently infected with C. hominis 
and C. parvum (7,11,12); recent reports indicate possible as-
sociations between these 2 organisms and different clinical 
manifestations. In Brazil, children infected with C. hominis 
had increased parasite shedding, more frequent presence of 
fecal lactoferrin, and delayed growth when compared with 
those infected with C. parvum (13). In a study of sporadic 
cryptosporidiosis in the United Kingdom, illness was more 
severe in persons infected with C. hominis than in those 
infected with C. parvum (14,15). A recent study reported 
different clinical manifestations among Cryptosporidium 
spp. in HIV-positive persons, and C. hominis was linked to 
more severe symptoms. The high virulence of C. hominis 
was evident within its subtype family Id, while absent in 
subtype families Ia and Ie (16).
In this study, we analyzed the diversity of Cryptospo-
ridium at the species, subtype family, and subtype levels in 
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children living in an area with endemic cryptosporidiosis. 
We also analyzed the association between clinical manifes-
tations and infections with speciﬁ  c Cryptosporidium spp. 
and C. hominis subtype families.
Methods
Study Design
Specimens and data were obtained from a longitudinal 
birth cohort study of diarrheal diseases conducted during 
1995–1998 in Pampas de San Juan de Miraﬂ  ores, Lima, 
Peru. This community was initially settled in the 1980s by 
immigrants from rural areas. It is located in the outskirts of 
Lima and had at the time of the study ≈40,000 inhabitants. 
In this community, the prevalence of HIV infection was 
<1% (2,7). The study protocol was reviewed and approved 
by the institutional review boards of Johns Hopkins Uni-
versity and the Centers for Disease Control and Prevention. 
All participants provided informed consent before partici-
pation in the study.
Microscopy
The study participants were asked to provide weekly 
fecal specimens for microscopic detection of ova and para-
sites, including Cryptosporidium spp. Stool specimens were 
washed and concentrated by using the modiﬁ  ed Ritchie 
formalin-ether method and examined for Cryptosporidi-
um spp. oocysts by microscopy of smears stained with a 
modiﬁ  ed acid-fast stain. Intensity of Cryptosporidium spp. 
oocyst shedding in stools was determined by counting the 
number of oocysts per 50 μL of concentrated sample. We 
used a 0 to 3+ scoring system in which 0, negative; 1+, 
1–50 oocysts; 2+, 51–150 oocysts; and 3+, >150 oocysts.
Genotyping and Subtyping
Cryptosporidium spp. were identiﬁ  ed by using a small 
subunit rRNA-based PCR–restriction fragment length 
polymorphism genotyping tool (7,12,17). Subtyping of C. 
hominis and C. parvum was based on sequence analysis of 
GP60 genes (18). Each specimen was analyzed by either 
method at least twice. Subtype families within C. hominis 
and C. parvum were determined on the basis of sequence 
differences in the nonrepeat region of the gene. Within each 
subtype family, subtypes differed from each other, mostly 
in the number of serine-coding trinucleotide repeats (TCA, 
TCG, or TCT microsatellite) located in the 5′ region of the 
gene. The previously established nomenclature system was 
used to differentiate subtypes within each subtype family 
(11,16,17). For C. parvum subtype family IIc, the original 
GP60 sequence for C. parvum subtype family IIc (Gen-
Bank accession no. AF164491) was assigned as IIcA5G3a. 
Subtypes that diverged from this sequence were assigned 
subsequent alphabetical extensions.
Associated Clinical Manifestations and Risk Factors
Daily information on clinical manifestations was gath-
ered by using structured questionnaires. These data were 
collected by study personnel during interviews of adult 
caregivers of the participants. Data included relevant gas-
trointestinal symptoms such as abdominal pain, fever, gen-
eral malaise, nausea, vomiting, number and consistency of 
bowel movements, and blood in stools.
Study of potential risk factors for infections was based 
on sanitation and socioeconomic data obtained at study en-
rollment. These factors included hygiene parameters (water 
piped inside the house and presence of ﬂ  ush toilets), pres-
ence of animals (dogs, chicken, ducks, guinea pigs, rabbits, 
parrots, and sheep), house infrastructure (sturdy walls and 
roof), and indirect economic indicators (house infrastruc-
ture and possession of electronic appliances).
Deﬁ  nitions
For the epidemiologic and statistical analyses, we 
included data from eligible children who had >6 months 
of participation in the study and <20% noncompliance of 
study procedures. For the epidemiologic analyses we used 
the following deﬁ  nitions. 
Duration of an infection episode was deﬁ  ned as an epi-
sode that started on the ﬁ  rst date that Cryptosporidium spp. 
oocysts were microscopically detected in stools and ended 
on the date of the last positive stool that was followed by at 
least 3 weekly specimens that were microscopically nega-
tive. The length of the infection episode was the number of 
days between the start and end dates.
An episode of diarrhea was deﬁ  ned as a child hav-
ing >3 liquid or semiliquid bowel movements on any day 
and the mother’s assessment that the child had diarrhea. 
Diarrhea was considered associated with an episode if it 
occurred within 7 days of a positive result for Cryptospo-
ridium spp.
Statistical Analysis
Statistical analyses included data from participants 
infected with 1 species of Cryptosporidium and compared 
children with a speciﬁ  c Cryptosporidium sp. or C. hominis 
subtype family with all other participants not infected with 
that species or subtype family. Subtype families were com-
pared because of the extensive sequence polymorphism in 
the nonrepeat regions of GP60, and subtypes within fami-
lies primarily differed from each other in the length of the 
serine stretch at the beginning of the protein. Data from the 
few children infected with >1 species or subtype determi-
nations that were conﬂ  icting with genotype categorizations 
were excluded from that particular comparison. Because all 
C. parvum in this population belonged to 1 subtype family, 
results were presented at the species level. Few participants 
were infected with C. canis and C. felis and these species 
1568  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 10, October 2008Cryptosporidium Species and Subtypes, Peru
are genetically divergent from C. hominis, C. parvum, and 
C. meleagridis. Therefore, the data for these persons were 
pooled.
Poisson regression was used to compare incidence 
rates of gastrointestinal symptoms (dependent variables) 
and infections with Cryptosporidium spp. or subtype fami-
lies (independent variables) detected in each infection epi-
sode. This model was used to incorporate individual inci-
dence rates of infections and the duration that each person 
participated in the study. These regression analyses were 
conducted by using SAS Proc Genmod (SAS Institute, 
Cary, NC, USA) for linear models. The generalized esti-
mating equations procedure was implemented to adjust for 
correlation among multiple infections for the same child. 
Statistical signiﬁ  cance for a priori tests was set at α = 0.05. 
Whenever multiple subtypes were compared, a separate 
Bonferroni adjustment was used to maintain an overall 
experiment-wide α of 0.05.
The χ2 or Fisher exact tests were used to analyze any 
association between Cryptosporidium spp. or subtypes and 
animal contacts or socioeconomic risk factors. Pooled t test 
was used to investigate the differences in age at ﬁ  rst in-
fection episode among Cryptosporidium spp. and subtype 
families. All statistical analyses were performed by using 
SAS version 9.1 (SAS Institute).
Results
A total of 533 children were enrolled, and their median 
age at enrollment was 14 days. They contributed 44,042 
stool specimens for detection of enteric parasites and 
324,067 child-days of clinical manifestation surveillance.
Prevalence of Cryptosporidiosis
Data from 368 participants who met the evaluable cri-
teria were included in the epidemiologic analyses. Cryp-
tosporidiosis was detected by microscopy for 109 partici-
pants, for a total of 156 infection episodes. Among them, 
71 children had 1 infection, 30 had 2 infections, 7 had 3 
infections, and 1 had 4 infections.
Cryptosporidium spp. Genotypes and Subtypes
Genotype data for Cryptosporidium spp. were ob-
tained from 127 (81%) of 156 infection episodes. Among 
those genotyped, C. hominis (70%) was the species most 
frequently detected, followed by C. parvum (13%) and C. 
meleagridis (8%). In contrast, C. canis and C. felis were 
detected in 2% and 5% of cases, respectively (Table 1). 
Among 106 infection episodes with either C. hominis (89) 
or C. parvum (17), subtype analysis was successfully ac-
complished for 78 of 89 infections with C. hominis and 
14 of 17 infections with C. parvum. Four subtype families 
were identiﬁ  ed within C. hominis: Ia, Ib, Id, and Ie, the least 
frequent was Id. All infections with C. parvum belonged to 
subtype family IIc. Novel subtype sequences were deposit-
ed in GenBank under accession nos. EU095258–EU095267 
(Table 2).
Several subtypes were found within subtype families 
Ia and Id of C. hominis and IIc of C. parvum. Subtype 
family Ia was the most diverse with 6 subtypes, followed 
by subtype families Id and IIc, each with 3 subtypes. In 
contrast, subtype families Ib and Ie each had only 1 sub-
type: IbA10G2 was the only subtype in subtype family Ib 
and IeA11G3T3 was the only subtype in subtype family Ie 
(Table 2).
Cryptosporidium spp. and Oocyst Shedding
The mean age for ﬁ  rst infections was 1.6 years of age 
(median 1.4 years, range 0.2–4.7 years). Infections with C. 
parvum occurred at a younger age than those with other gen-
otypes, and infections with C. canis or C. felis occurred in 
older children. However, these differences were not statisti-
cally signiﬁ  cant after the Bonferroni correction (Table 3).
The mean duration of the ﬁ  rst infection episode was 8.1 
days (median 5.5 days, range 1–40 days). Infections with 
C. hominis (mean 10.3 days) lasted longer than infections 
with other species of Cryptosporidium (mean 5.8 days; p 
= 0.001). The length of the infection episodes among chil-
dren infected with different subtype families of C. hominis 
was not signiﬁ  cantly different (9.3, 13.1, 7.7, and 12.8 days 
for Ia, Ib, Id, and Ie, respectively).
Similar patterns were observed for intensity of parasite 
excretion. Children infected with C. hominis had higher 
parasite excretion scores (mean 1.93) than those infected 
with other species of Cryptosporidium (mean 1.42; p = 
0.021). Among children infected with different subtype 
families of C. hominis, the intensity of parasite shedding 
was similar.
Sequential Cryptosporidium spp. Infections
Among children with complete genotyping data, se-
quential infections were detected in 17 children: 15 had 
2 episodes of Cryptosporidium spp. infection and 2 had 3 
episodes (total of 19 reinfection events). The median in-
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Table 1. Frequency of infections with Cryptosporidium spp. in 
533 children, Peru 
No. (%) infection episodes 
Species First Overall
C. hominis 61 (64.9)  89 (70.1) 
C. parvum 15 (16.0)  17 (13.4) 
C. meleagridis 9 (9.6)  10 (7.9) 
C. canis 2 (2.1)  2 (1.6) 
C. felis 4 (4.3)  6 (4.7) 
C. hominis and C. parvum 2 (2.1)  2 (1.6) 
C. canis and C. meleagridis 1 (1.1)  1 (0.8) 
No. genotyped  94 127
Total episodes  109 156RESEARCH
terval between infections was 10 months (range 2.1–26 
months). The same Cryptosporidium sp. was detected in 
6 of 15 children with 2 episodes and 1 of 2 children with 3 
infections, all involving C. hominis (Table 4). When analy-
sis of reinfections included C. hominis subtype family data, 
only 2 sequential infections occurred with the same sub-
type family: child 5395 had C. hominis subtype family Id 
in the ﬁ  rst and second infections, and child 5076 had C. 
hominis subtype family Ie in the second and third episodes 
of cryptosporidiosis.
Cryptosporidium spp. and Subtypes 
and Associated Clinical Manifestations
Distribution of species and subtype families at ﬁ  rst in-
fection among 109 Cryptosporidium spp.–infected children 
was similar to the distribution in all infection episodes. A 
second model analyzed the data from all infection episodes 
(Table 5).
On the basis of microscopy results, 36% of infected 
children had diarrhea, 28.4% had general malaise, 16.5% 
had abdominal pain, 15.7% had vomiting, and 7.9% had 
nausea. None of the study participants reported fever or 
blood in stools. Overall, 44.1% reported >1 of the manifes-
tations assessed in the study.
Associated clinical manifestations at ﬁ  rst  infection 
varied among different Cryptosporidium spp. First infec-
tions with C. hominis were associated with nausea, vomit-
ing, general malaise, and diarrhea (Table 5). In contrast, 
infections with other species were associated with diarrhea 
only.
Patterns of clinical manifestations also varied among 
C. hominis subtype families. Infections with subtype fam-
ily Ib were associated with nausea, vomiting, general mal-
aise, and diarrhea. Infections with other subtype families 
(Ia, Id, and Ie) were generally associated with diarrhea 
only. A similar trend was also seen in the cumulative 
analysis of all infection episodes at the species and sub-
type family levels. A possible exception was C. hominis 
subtype family Ia, which showed an association with nau-
sea and vomiting at ﬁ  rst infections but did not show such 
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Table 2. Distribution of subtype families and subtypes of Cryptosporidium hominis and C. parvum in 533 children, Peru 
No. episodes (%) 
Species Subtype families  At first infection  All
Subtype: no. (%)  
within subtype family 
GenBank
accession no. 
C. hominis  Ia 15 (24.6)  21 (26.9)  IaA11R4: 3 (14)  EU095258*
IaA12R4: 7 (33) EU095259*
IaA13R4: 1 (5) EU095260*
IaA13R7: 1 (5) EU095261*
IaA14R6: 5 (24) EU095262*
IaA15R3: 3 (14) EU095263*
Ib 16 (26.2)  23 (29.5)  IbA10G2: 23 (100)  AY262031 
Id 7 (11.5)  12 (15.4)  IdA10: 9 (75)  EU095264*
IdA15: 1 (8)  DQ280498 
IdA20: 2 (16)  EU095265*
Ie 15 (24.6)  19 (24.4)  IeA11G3T3:19 (100)  DQ665689 
lb + le   1 (1.6)  1 (1.3)  1 (1.3) 
Ib + id  1 (1.6)  1 (1.3)  1 (1.3) 
Id + ie  1 (1.6)  1 (1.3)  1 (1.3) 
C. hominis and C. parvum  Id + IIc  1
C. parvum  IIc 14 (100)  14 (100)  IIcA5G3a: 12 (86)  AY738195 
IIcA5G3b: 1 (7) EU095266*
IIcA5G3c: 1 (7)  EU095267*
*From this study. 
Table 3. Age at first infection by Cryptosporidium spp. and subtype family in 533 children, Peru 
Species or subtype family  No. episodes  Age, y, mean (range) p value
C. hominis 61* 1.93 (0.19–9.51) 0.026†
Subtype family Ia  15 2.13 (0.67–8.05)  0.113
Subtype family Ib  16 1.38 (0.60–2.82)  0.176
Subtype family Id  7 1.41 (0.19–3.34)  0.645
Subtype family Ie  15 1.81 (0.25–9.51)  0.723
C. parvum 15 1.22 (0.44–2.49) 0.034†
C. meleagridis 9 1.43 (0.78–2.75) 0.615
C. canis or C. felis‡ 6 2.26 (0.68–3.74) 0.039†
Mixed infections  2 1.62 (1.44–1.79)  Not done 
*Eight C. hominis infections did not have subtype family data. 
†Not significant after Bonferroni adjusted Į = 0.05/5 = 0.01. 
‡Includes 1 mixed infection with C. meleagridis and C. canis.Cryptosporidium Species and Subtypes, Peru
an association in the cumulative analysis of all infection 
episodes (Table 5).
Discussion
Rates of clinical manifestations in our study were lower 
than rates reported for a birth cohort in Brazil, where 81% 
of 42 participants infected with C. hominis or C. parvum 
had diarrhea (13). This difference can be attributed to dif-
ferences in study designs. Our study analyzed weekly stool 
samples for the presence of Cryptosporidium spp. and other 
parasites in a cohort of healthy children. In contrast, the 
cohort study in Brazil was designed to identify causes of 
diarrhea, and the specimens were collected within 2 weeks 
of clinical identiﬁ  cation of diarrhea.
C. hominis was the predominant species in this com-
munity-based longitudinal study, followed by C. parvum 
(7). This predominance of C. hominis has been observed 
in persons in other developing countries, such as pediatric 
populations from Malawi (19), Kenya (20), India (21), Hai-
ti (22), and Brazil (13), children and elderly persons from 
South Africa (23), and hospitalized HIV-infected children 
from South Africa and Uganda (24,25). As reported in pre-
vious studies (21,24,26,27), we also detected few concur-
rent infections with multiple Cryptosporidium spp. or C. 
hominis subtype families.
We observed a comparatively large proportion of par-
ticipants infected with C. meleagridis, a ﬁ  nding that was 
also reported at a high frequency in HIV-infected adults in 
Lima, Peru (12,16). This species has been rarely reported 
for studies from other locations such as Portugal (28), India 
(21,26,29), Taiwan (30), or Iran (31) that included either 
children or adults with or without HIV infections. It should 
be noted that the diversity of Cryptosporidium spp. is also 
affected by the methods used. We used a genotyping tool 
proven to distinguish several dozen species and genotypes. 
However, methods based on genes coding for a 70-kDa 
heat-shock protein (32), Cryptosporidium spp. oocyst wall 
protein (33), or a smaller fragment of the small subunit 
rRNA gene (34) discriminate fewer Cryptosporidium spp. 
and genotypes.
Overall, distribution of species and C. hominis subtype 
families in our study was similar to that found in an HIV 
study in Lima, Peru (12,16). These 2 studies were con-
ducted in the same area but in different study populations. 
In both studies, all C. parvum specimens belonged to sub-
type family IIc, which is considered anthroponotic in ori-
gin (17). The normally zoonotic subtype family IIa was not 
seen in our study population. This ﬁ  nding is also supported 
by our risk factor data, which showed the lack of bovines in 
the study households and the absence of cattle farms in or 
near the community of Pampas de San Juan. The similarity 
of the species and subtype distribution in both studies is 
highly suggestive that the prevalence of Cryptosporidium 
spp. and subtypes in a speciﬁ  c location is independent of 
the immune status of the study population.
The role of parasite genetics in clinical manifestations 
of cryptosporidiosis is not clear. Studies of human volun-
teers showed that exposure provided some degree of pro-
tection against infection and illness; the infection rates and 
frequencies of infection-associated clinical manifestations 
were lower for subsequent infections (35). Thus, clinical 
manifestations caused by parasite differences would be bet-
ter observed in primary infections. Our longitudinal birth 
cohort study enrolled children at an early age (median 14 
days), which enabled us to study genotypes and subtypes 
present at ﬁ  rst infections and their associations with differ-
ent clinical manifestations.
First infections with all species and C. hominis subtype 
families were associated with diarrhea. However, only C. 
hominis subtype family Ib was also associated with nau-
sea, vomiting, and general malaise, but C. hominis subtype 
families Ia, Id, and Ie, and other Cryptosporidium spp. were 
not. Previously, other studies had suggested that C. homi-
nis might be more pathogenic than other species or might 
induce different clinical manifestations (13,15,21). Our re-
sults indicate that within C. hominis, subtype family Ib may 
be more pathogenic than Ia, Id, and Ie. Subtype family Ib 
of C. hominis is the most frequently detected Cryptospo-
ridium spp. in waterborne outbreaks of cryptosporidiosis in 
industrialized nations (36).
A previous study of cryptosporidiosis in HIV-infected 
persons in Peru showed that infections with different spe-
cies or subtype families were associated with different clin-
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Table 4. Cryptosporidium spp. and subtype families of C. hominis
detected in reinfection events in 533 children, Peru 
Infection
Event First Second Third
5444 C. parvum (IIc)  C. hominis (Id and Ie) C. hominis
(Ib)
5076 C. hominis (Id)  C. hominis (Ie)  C. hominis
(Ie)*
E392 C. hominis (Ib)  C. hominis (Ie) 
K283 C. hominis (Ib)  C. hominis (Id) 
5395 C. hominis (Id)  C. hominis (Id)* 
5125 C. hominis C. hominis (Ia) 
D037 C. hominis C. hominis (Ia) 
5492 C. hominis C. hominis (Id) 
5471 C. hominis (Ib)  C. parvum
5399 C. hominis (Ie)  C. felis
5370 C. parvum C. hominis (Id) 
5266 C. meleagridis C. hominis (Ib) 
H131 C. meleagridis C. hominis (Ia) 
5082 C. meleagridis C. hominis
5300 C. felis C. hominis
5085 C. canis C. hominis
5049 C. hominis and 
C. parvum
C. felis
*Reinfections with the same subtype family. RESEARCH
ical manifestations. Patients infected with subtype families 
Ib and Id of C. hominis, C. parvum, or C. canis/C. felis were 
more likely to have chronic diarrhea, and patients infected 
with C. parvum were more likely to have infection-associ-
ated vomiting (16). Overall, subtype family Id was the most 
virulent in the HIV study and was strongly associated with 
diarrhea in general and chronic diarrhea in particular. Sub-
type family Ib was also marginally associated with diarrhea 
and vomiting but not with chronic diarrhea. In this study, 
however, Id was only associated with diarrhea. This differ-
ence may be caused by the fact that chronic cryptospori-
diosis, the life-threatening manifestation of the disease in 
AIDS patients, was never detected in this study of pediatric 
patients, and few children in this study were infected with 
subtype family Id, which might have prevented us from as-
sessing its clinical manifestations fully. Nevertheless, our 
study corroborated the previous observation of deﬁ  ned pat-
terns of clinical manifestations associated with different 
Cryptosporidium spp. and C. hominis subtype families.
We also conducted a risk factor analysis for predic-
tors of infection, including age at ﬁ  rst infection, in which 
we did not identify statistically signiﬁ  cant associations be-
tween any Cryptosporidium spp. or subtype families and 
any of the variables analyzed, although they covered basic 
aspects of sanitation and zoonotic, foodborne, and water-
borne transmission. One possible explanation is that our 
questionnaires did not obtain data on factors that were rel-
evant. However, the same questionnaire successfully iden-
tiﬁ  ed infection risk factors for other organisms in the same 
community (2). A more likely explanation is that because 
most Cryptosporidium spp. in this study were anthroponot-
ic in origin, children may be constantly exposed to these 
ubiquitous parasites through different transmission routes. 
Therefore, single exposure variables were not identiﬁ  ed as 
risk factors. This constant exposure may also ﬁ  t the age dis-
tribution pattern of cryptosporidiosis in the community, in 
which most cases are found in children <2 years of age, oc-
casionally found in older children, and almost never found 
in immunocompetent adults. This ﬁ  nding is in contrast to 
transmission of Cryptosporidium spp. in industrialized na-
tions, where infections have been frequently associated 
with waterborne transmission from either drinking water 
(37) or recreational water (38).
In conclusion, clinical manifestations of cryptospori-
diosis in healthy populations in disease-endemic areas are 
likely diverse, and the spectrum of these clinical mani-
festations can be attributed in part to the different species 
of Cryptosporidium and subtype families of C. hominis. 
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Table 5. Associations between infections with Cryptosporidium spp. or C. hominis subtype families and clinical manifestations 
expressed as incidence rate ratios in 533 children, Peru* 
First infection  All infections 
Clinical manifestation  IRR p value IRR p value
Children infected with C. hominis vs. those with cryptosporidiosis but not infected with C. hominis
 Nausea  5.469 <0.001† 3.531 0.037‡
 Vomiting  2.252 <0.001† 2.359 0.023‡
 General  malaise  2.523 <0.001† 2.071 0.035‡
 Diarrhea  3.690 <0.001† 4.886 <0.001†
Children infected with C. parvum vs. those with cryptosporidiosis but not infected with C. parvum
 Diarrhea  3.249 <0.001† 4.562 <0.01†
Children infected with C. meleagridis vs. those with cryptosporidiosis but not infected with C. meleagridis
 Diarrhea  2.484 0.006† 7.684 <0.001†
Children infected with C. canis or C. felis vs. those with cryptosporidiosis but not infected with these species  
 Diarrhea  3.122 0.002† 1.528 0.662
Children infected with C. hominis subtype family Ia vs. those not infected with that subtype family 
 Nausea  5.020 <0.001† 3.203 0.183
 Vomiting  2.280 0.013‡ 2.100 0.141
 Diarrhea  2.442 <0.001† 3.061 0.002†
Children infected with C. hominis subtype family Ib vs. those not infected with that subtype family 
 Nausea  12.516 <0.001† 8.402 0.006†
 Vomiting  4.752 <0.001† 4.868 0.004†
 General  malaise  4.939 <0.001† 4.139 0.006†
 Diarrhea  5.510 <0.001† 6.506 <0.001†
Children infected with C. hominis subtype family Id vs. those not infected with that subtype family 
 Diarrhea  2.999 <0.001† 3.171 0.022‡
Children infected with C. hominis subtype family Ie vs. those not infected with that subtype family 
 General  malaise  1.830 0.010‡ 1.613 0.333
 Diarrhea  3.117 <0.001† 4.160 0.001†
*Determined by Poisson regression analyses. IRR, incidence rate ratio. 
†Statistically significant at Bonferroni corrected Į = 0.01. 
‡Statistically significant at p<0.05. Cryptosporidium Species and Subtypes, Peru
Although further laboratory and longitudinal cohort stud-
ies in other disease-endemic areas are needed to validate 
our observations, these results demonstrate that parasite 
genetics may play an important role in the clinical mani-
festations of human cryptosporidiosis. Future studies 
should be conducted in different geographic settings; they 
should overcome some potential limitations of this study, 
such as lack of data on other gastrointestinal pathogens, 
which might have confounded the clinical ﬁ  ndings, and 
small sample sizes, which had limited the power of the 
statistical analyses.
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